title: Iatrogenic deaths following treatment for hypertrophic obstructive cardiomyopathy: case reports and an approach to the autopsy and death certification.
abstract: Hypertrophic cardiomyopathy (HCM) is a disease process which results in a large, heavy heart, with hypertrophy of the interventricular septum (IVS) and left ventricle. HCM accounts for a significant number of cases of sudden cardiac death each year, most infamously in young athletes. The prevalence of the disease has increased over the past several years due to advances in clinical diagnosis and molecular genetic studies. Over this same period, new forms of treatment also have emerged. One such treatment is alcohol septal ablation (ASA). ASA is a procedure performed by a cardiologist, via cardiac catheterization, by injecting pure ethanol into selected arteries which supply the IVS, resulting in a targeted myocardial infarction. This infarct then retracts and forms a scar, decreasing the outflow obstruction and improving the patient's clinical symptoms.The authors report 2 cases of death following ASA treatment of HCM. The first, a 56-year-old male, had his ASA procedure 10 days prior to death. The second decedent, a 76-year-old female, had her procedure only 30 hours before death. These case reports are followed by a discussion about HCM, including pathology, treatments, and treatment-related pathology, before closing with a discussion about death certification in the cases presented and therapy-related deaths in general.
authors.affiliation: Medical University of South Carolina, Forensic Pathology Section, Charleston, 29412, USA. batalini@musc.edu
authors.forename: Nick I
authors.initials: NI
authors.lastname: Batalis
authors.forename: Russell A
authors.initials: RA
authors.lastname: Harley
authors.forename: Kim A
authors.initials: KA
authors.lastname: Collins
mesh_terms: D000368:Aged; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000009:adverse effects*; D001024:Aortic Valve Stenosis / Q000473:pathology; D002114:Calcinosis / Q000473:pathology; D006328:Cardiac Catheterization; D002312:Cardiomyopathy, Hypertrophic / Q000628:therapy*; D017115:Catheter Ablation / Q000009:adverse effects*; D003328:Coronary Thrombosis / Q000473:pathology; D000431:Ethanol / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005355:Fibrosis; D006346:Heart Septum / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000473:pathology; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000473:pathology; D017202:Myocardial Ischemia / Q000473:pathology; D009206:Myocardium / Q000473:pathology
chemical_list: D000891:Anti-Infective Agents, Local; D000431:Ethanol